Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CSK | P41240 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484052 | 0.84 | RAD52 (0.45) | LCKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4491071 | 0.80 | LCK (0.56) | LCKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4480855 | 0.77 | LCK (0.43) | LCKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4488306 | 0.76 | APP (0.43) | LCKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4488278 | 0.75 | JAK3 (0.53) | LCKFGFR1JAK3KDRBTK | |
| SCHEMBL5686308 | 0.75 | JAK3 (0.57) | LCKFGFR1JAK3KDRBTK | |
| SCHEMBL4499858 | 0.74 | JAK3 (0.54) | LCKFGFR1JAK3KDRBTK | |
| SCHEMBL4496379 | 0.74 | LCK (0.57) | LCKFGFR1JAK3KDRBTK | |
| SCHEMBL4497365 | 0.74 | LCK (0.41) | LCKFGFR1JAK3BTKTNK2 | |
| SCHEMBL4500498 | 0.73 | JAK3 (0.55) | LCKFGFR1JAK3KDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | LCK 33/4885FGFR1 1409/4885FGFR2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.